BioCryst Reports Second Quarter 2022 Financial Results and Upcoming Key Milestones
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/30/2026
- Wall Street ends higher as US, Iran attacks ease; major tech-related shares jump
- Tech funds suffer record outflows as investors trim equity positions
- Comcast shares surge 23% on blockbuster plan to spin off NBCUniversal and Sky
- New leader board: Citi refreshes AI compute semiconductor picks
- Martin Marietta confirms $13.5B deal for Lhoist North America
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- EchoStar Prepares Dish DBS Bankruptcy Filing as Soon as Tuesday - WSJ
- Strategy stock jumps 7% as firm shifts to active capital management
- New leader board: Citi refreshes AI compute semiconductor picks
- Honeywell completes aerospace spin-off, splits into 3 companies
BioCryst Pharma (BCRX) Tops Q2 EPS by 2c
August 4, 2022 7:09 AM EDTBioCryst Pharma (NASDAQ: BCRX) reported Q2 EPS of ($0.32), $0.02 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $65.2 million versus the consensus estimate of $63.33 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
... More